Browse Category

ASX:TLX News 11 December 2025 - 27 January 2026

Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix Pharmaceuticals shares fell 7.7% to A$10.61 at Wednesday’s close after the company reported unaudited FY2025 revenue in line with guidance and noted early momentum for Gozellix. China’s drug regulator accepted the Illuccix application, triggering a formal review. Investors weighed ongoing U.S. regulatory developments and recent clinical trial results.
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals Limited (ASX:TLX, Nasdaq:TLX) entered the spotlight again on December 17, 2025, as TLX stock extended its December sell-off amid a fast-moving mix of clinical-trial updates, regulatory overhang, and investor litigation headlines. Telix Pharmaceuticals+2Investing.com+2 On the ASX, Telix shares closed at A$11.73, down 6.61% on the session, with a wide intraday range from A$11.535 to A$12.730 and volume of roughly 6.36 million shares—a notably volatile day by recent standards. Investing.com+1 In the U.S., Telix’s Nasdaq-listed shares/ADS were also under pressure, with U.S. market coverage noting a gap-down move and a roughly 6%–7% decline in early trading action on Dec.
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

December 11, 2025 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack of class‑action lawsuits. At the same time, new clinical milestones and a fresh collaboration with Varian are reinforcing the long‑term radiopharmaceutical growth story. This overview pulls together today’s news, the latest clinical and legal developments, and current analyst forecasts as of 11 December 2025. Telix share price today: depressed after a volatile year By midday in New York on 11

Stock Market Today

L’Oreal share price slips into weekend as OR.PA heads for annual results test

L’Oreal share price slips into weekend as OR.PA heads for annual results test

7 February 2026
L’Oréal shares closed at 394.05 euros in Paris on Friday, down 0.16%, marking a second straight session of losses. The company will release its 2025 annual results after markets close on Feb. 12, with a financial meeting set for Feb. 13. About 319,000 shares traded Friday in a range between 385.70 and 395.10 euros. The STOXX 600 rose 0.9% to 617.12 points.
RBC stock heads into new week near C$233 after Canada jobs surprise

RBC stock heads into new week near C$233 after Canada jobs surprise

7 February 2026
Royal Bank of Canada shares closed Friday up 0.7% at C$232.72, trailing gains by other major Canadian banks. Canada’s main stock index surged 1.5% as metals rebounded. January jobs data showed a loss of 24,800 positions but a lower 6.5% unemployment rate. RBC’s Q1 earnings are due Feb. 26.
IHC stock price holds near 400 dirhams after Abu Dhabi group flags phishing emails

IHC stock price holds near 400 dirhams after Abu Dhabi group flags phishing emails

7 February 2026
International Holding Company PJSC warned investors of phishing scams using its name and logo, according to an ADX disclosure. IHC shares closed flat at 399.60 dirhams on Friday, trading in a narrow range with 237,109 shares changing hands. UAE equities ended the week slightly higher as traders watched Iran-U.S. talks and oil prices.
Go toTop